Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LUMVOA

(Veligrotug)

VViridian Therapeutics, Inc.

0

Indications

4

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Thyroid Eye Disease4 trials

An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Completed·VViridian Therapeutics, Inc.·Phase 3·NCT06179875·139 enrolled

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)

Completed·VViridian Therapeutics, Inc.·Phase 3·NCT06021054·188 enrolled

A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease

Completed·VViridian Therapeutics, Inc.·Phase 3·NCT05176639·113 enrolled

Show 1 more trial

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Thyroid Eye Disease (TED)

Completed·VViridian Therapeutics, Inc.·Phase 3·NCT06384547·231 enrolled

Regulatory

FDA Approval Timeline[3]

Jun 26, 2026

LUMVOA

BLA BLA761530

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Veligrotug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Veligrotug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (BLA BLA761530). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Viridian Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Company: VViridian Therapeutics, Inc.

Related News